When a dog is diagnosed with hyperadrenocorticism (Cushing's disease), trilostane—marketed under the proprietary brand name Vetoryl—is the only FDA-approved medical therapy available in the United States. Approved under NADA 141-291, trilostane acts by competitive enzyme inhibition of 3β-hydroxysteroid dehydrogenase (3β-HSD), blocking the adrenal cortex from synthesizing excessive cortisol and aldosterone. Because Cushing's disease is incurable and requires lifelong daily pharmacotherapy, dog owners and veterinary teams frequently research post-marketing safety data to understand the real-world incidence of adverse reactions, the risk of iatrogenic hypoadrenocorticism (Addison's disease), and the clinical context behind reported fatalities.

Across 12,001 unique U.S. adverse-event reports naming trilostane filed with the FDA Center for Veterinary Medicine (CVM), domestic canines account for 11,720 cases (97.7%), consistent with Vetoryl's dog-only labeled indication. In the single-agent canine cohort (5,383 reports where trilostane was the sole active ingredient), the most commonly reported clinical signs are vomiting (945 reports), lethargy (925), hyperkalaemia (761), underdose (684), elevated alkaline phosphatase (683), diarrhea (642), anorexia (576), weight loss (570), elevated ALT (530), elevated BUN (487), and a low sodium-to-potassium ratio in 335 reports.

The prominent pairing of hyperkalaemia (elevated potassium) and low Na:K ratios represents the distinct biochemical fingerprint of iatrogenic hypoadrenocorticism—trilostane's primary pharmacologic risk. While fatal outcomes are recorded in passive surveillance (392 euthanized and 226 died in single-agent dog reports, representing approximately 11.5% combined), these cases overwhelmingly involve elderly, systemically fragile Cushing's patients with concurrent organ compromise rather than acute drug toxicity. With structured ACTH-stimulation testing and electrolyte monitoring, the serious risks flagged in these reports are largely preventable and manageable.

How many trilostane adverse-event reports are there, and what leads them?

The openFDA Animal and Veterinary Drug Adverse Event database aggregates mandatory post-marketing submissions from drug sponsors and voluntary reports from veterinary clinicians and dog owners. In the regulatory reporting snapshot through July 2026, 12,001 unique adverse-event reports list trilostane as an active substance.

Because trilostane is approved in the U.S. exclusively for dogs (covering both pituitary-dependent hyperadrenocorticism and adrenal-dependent hyperadrenocorticism due to adrenocortical tumors), canine patients dominate the dataset.

When reviewing raw adverse-event numbers, clinicians must recognize that in passive pharmacovigilance, report volume reflects cumulative prescribing volume, marketing longevity (Vetoryl was approved by the FDA in December 2008), and heightened owner vigilance rather than an inherent toxicity rate. For a comprehensive review of testing protocols, see our guide on trilostane dosing and ACTH-stimulation monitoring.

┌──────────────────────────────────────────────────────────────────────────┐
│             TRILOSTANE FDA ADVERSE-EVENT ANNUAL REPORT TREND             │
├──────────────────────────────────────────────────────────────────────────┤
│ 2019: ████████████████████ 1,057 reports                                 │
│ 2020: ██████████████████ 971 reports                                     │
│ 2021: █████████████████ 940 reports                                      │
│ 2022: ████████████████ 856 reports                                       │
│ 2023: ███████████████ 815 reports                                        │
│ 2024: ███████████████ 800 reports                                        │
│ 2025: █████████████ 690 reports                                          │
│ 2026: ███ 172 reports (partial year through July 2026)                   │
└──────────────────────────────────────────────────────────────────────────┘

The modest downward trend in annual submissions from 2019 to 2025 reflects established clinical familiarity with lower initial starting doses (e.g., 1–2 mg/kg/day or twice-daily micro-dosing protocols) rather than the higher legacy doses originally published on older labels.

What do the reports reveal about iatrogenic Addison's disease and electrolyte imbalance?

To isolate the adverse effects directly attributable to trilostane from the confounding effects of concurrent medications (such as ACE inhibitors, NSAIDs, or heartworm preventives), we examined the single-agent canine cohort comprising 5,383 reports where trilostane was the only reported active drug.

The Biochemical Signature of Iatrogenic Addison's

In a healthy dog, the adrenal cortex produces glucocorticoids (cortisol) in the zona fasciculata and mineralocorticoids (aldosterone) in the zona glomerulosa. Aldosterone acts on the distal renal tubules to promote sodium reabsorption and potassium excretion.

When trilostane inhibits 3β-HSD, it suppresses synthesis across all adrenocortical steroid pathways:

1. Glucocorticoid Deficiency (Atypical Hypoadrenocorticism): A rapid drop in cortisol triggers nausea, vomiting, profound lethargy, and anorexia. This is the most common presentation and usually resolves quickly upon temporary drug withdrawal and dose reduction.
2. Mineralocorticoid Deficiency (Typical Hypoadrenocorticism): When aldosterone is suppressed, the kidneys waste sodium and retain potassium. This shifts the normal serum sodium-to-potassium ratio (normally >27:1, often 30:1 to 40:1) down below 27:1, and in severe crises, below 20:1.
3. Clinical Manifestations: In our dataset, hyperkalaemia appears in 761 single-agent reports (14.1%), low Na:K ratios in 335 reports (6.2%), and hyponatremia in 186 reports (3.5%). Unchecked, severe hyperkalemia impairs cardiac electrical conduction, leading to bradycardia, profound weakness, and vascular collapse.

For clinical management protocols when this occurs, refer to our detailed guide on iatrogenic Addison's disease from trilostane and compare it against the natural pathophysiology of primary Addison's disease (hypoadrenocorticism) in dogs.

How do the FDA report tallies compare with Vetoryl's field-study side-effect rates?

To establish whether real-world post-marketing reports deviate from pre-approval clinical trials, we compared the FDA adverse-event database findings against the original Freedom of Information (FOI) Summary for NADA 141-291 and peer-reviewed multi-center clinical trials.

During the FDA pre-approval multi-center field study (enrolling 107 dogs treated with Vetoryl capsules at initial label doses of 2.2–6.7 mg/kg once daily), investigators recorded adverse reactions over a 6-month evaluation period:

The marked difference in hyperkalaemia and electrolyte reporting between the pre-approval field study (4.7%) and post-marketing reports (14.1%) does not indicate that the drug has become more toxic. Rather, it demonstrates that contemporary veterinary practices perform routine baseline and follow-up electrolyte panels alongside ACTH-stimulation tests, capturing subclinical biochemical changes before dogs develop overt clinical crises.

This pharmacovigilance pattern is consistent with methodology seen in other chronic small-animal therapies, such as our telmisartan FDA adverse-event analysis and grapiprant FDA adverse-event analysis. For an overarching view of how veterinary pharmacovigilance operates, see how FDA animal drug adverse-event reporting works.

What do the reported deaths actually reflect, and are they drug-caused?

One of the most distressing statistics for pet owners reviewing adverse-event summaries is the number of recorded deaths. Within the single-agent canine trilostane cohort (5,383 reports), recorded patient outcomes span five distinct categories:

Unpacking the 11.5% Fatal Outcome Signal

In clinical toxicology, interpreting mortality data requires understanding the underlying patient demographic:

1. Geriatric, Multi-Morbid Population: Canine Cushing's disease is an endocrine disorder of older dogs, with a median age of onset between 9 and 12 years. Dogs presenting for trilostane therapy frequently carry concurrent chronic kidney disease (CKD), degenerative mitral valve disease (DMVD), systemic hypertension, diabetes mellitus, or pituitary macroadenomas.
2. Complications of Hyperadrenocorticism: Chronic hypercortisolemia predisposes dogs to life-threatening complications that occur independently of medication, including systemic thromboembolism (pulmonary thromboembolism), severe pyelonephritis, congestive heart failure, and diabetic ketoacidosis.
3. True Drug-Related Mortality (Acute Adrenal Necrosis): In a small fraction of cases (<1% of all treated dogs), trilostane administration is associated with acute, bilateral adrenal cortical necrosis. The exact mechanism remains idiopathic but is hypothesized to involve intense intracellular ACTH stimulation or rapid vascular spasm. Adrenal necrosis causes permanent, irreversible hypoadrenocorticism requiring lifelong replacement therapy with fludrocortisone or DOCP (Percorten-V / Zycortal) and prednisone.

Consequently, passive surveillance death reports cannot be treated as direct drug-induced fatalities; rather, they reflect the serious nature of hyperadrenocorticism in a senior canine population.

Regulatory and Pricing Context: Brand-Only Status (NADA 141-291)

A frequent point of friction for dog owners managing Cushing's disease is the long-term monthly medication cost. A review of the FDA Green Book (Approved Animal Drug Products database, verified against the July 2026 data snapshot) reveals critical structural realities about trilostane availability:

• Single Sponsor: Vetoryl is approved under NADA 141-291, sponsored by Dechra Ltd. (first approved on December 5, 2008, and published in the Federal Register under document E9-10927).
• No Approved Generics: There are zero approved Abbreviated New Animal Drug Applications (ANADAs) for generic trilostane in the United States. Vetoryl remains a brand-only pharmaceutical.
• Compounding Warnings: Because Vetoryl is manufactured in discrete capsule sizes (5 mg, 10 mg, 20 mg, 30 mg, 60 mg, 120 mg), small or intermediate-sized dogs sometimes fall between standard strengths. The FDA and the American Animal Hospital Association (AAHA) strongly discourage the use of bulk-powder compounded trilostane when manufactured Vetoryl capsules are commercially available. Multiple published peer-reviewed studies (e.g., Journal of the American Animal Hospital Association) have documented that compounded trilostane formulations exhibit severe batch-to-batch potency variations (ranging from 39% to 152% of labeled strength), risking either treatment failure or catastrophic iatrogenic Addisonian crisis.

What does an owner watch for, and when is weakness or collapse an emergency?

For pet owners and veterinary triage technicians, distinguishing between normal therapeutic adaptation and an emerging adrenal crisis is vital.

┌──────────────────────────────────────────────────────────────────────────┐
│                   VETORYL CLINICAL MONITORING MATRIX                     │
├──────────────────────────────────────────────────────────────────────────┤
│ GREEN (Expected Adaptation):                                             │
│  • Gradual decrease in excessive water intake (polydipsia).              │
│  • Normalization of ravenous appetite (polyphagia).                      │
│  • Mild, transient softness of stool during the first 3–5 days.          │
│  ──► ACTION: Continue prescribed dose; attend scheduled re-check.        │
├────────────────────────────────────────────────────────────────────────┤
│ YELLOW (Early Cortisol Drop / Warning Signs):                            │
│  • Dog refuses one meal or shows marked inappetence.                     │
│  • Single episode of vomiting or mild diarrhea.                          │
│  • Noticeable lethargy (reluctance to play, sleeping more than usual).   │
│  ──► ACTION: STOP Vetoryl immediately. Contact your veterinarian.        │
│             Do not administer the next capsule until instructed.         │
├────────────────────────────────────────────────────────────────────────┤
│ RED (Medical Emergency / Possible Addisonian Crisis):                    │
│  • Repeated vomiting or severe, watery diarrhea.                         │
│  • Profound muscle weakness, shivering, or ataxia (wobbly gait).         │
│  • Sudden collapse, severe bradycardia (slow heart rate), or hypothermia.│
│  ──► ACTION: EMERGENCY CARE REQUIRED IMMEDIATELY.                        │
│             Transport dog to an open emergency facility.                 │
└──────────────────────────────────────────────────────────────────────────┘

Standard Veterinary Monitoring Schedule

To prevent adverse events, veterinary consensus guidelines recommend a strict re-check timetable:

1. Baseline Assessment: CBC, comprehensive serum chemistry with electrolytes (Na+, K+, Cl-), urinalysis, and baseline ACTH-stimulation test prior to starting Vetoryl.
2. Initial Re-checks (Day 10–14 and Day 30): Full physical exam, electrolyte panel, and post-ACTH stimulation test performed 4 to 6 hours after the morning Vetoryl capsule (with food).
3. Dose Titration Check (Day 90): Repeat ACTH-stimulation test and electrolytes.
4. Maintenance Monitoring (Every 3 to 6 Months): Regular physical exam, electrolytes, and ACTH-stimulation testing for the remainder of the dog's life, or immediately if any dose adjustment occurs.

Frequently Asked Questions

Can trilostane cause an Addisonian crisis even at a normal starting dose?

Yes. While most cases of iatrogenic hypoadrenocorticism occur due to relative overdosing, individual dogs exhibit unpredictable sensitivity to 3β-HSD inhibition. Furthermore, rare idiosyncratic acute adrenal necrosis can occur at standard therapeutic doses (1–3 mg/kg/day). Routine electrolyte monitoring at days 10–14 and day 30 catches early cortisol and aldosterone suppression before clinical crisis develops.

Why does the FDA data show hyperkalaemia and low sodium-to-potassium ratios so often?

Trilostane blocks the synthesis of aldosterone alongside cortisol. Aldosterone is responsible for renal potassium excretion and sodium retention. When aldosterone drops, potassium accumulates in the blood (hyperkalaemia) while sodium is lost in urine (hyponatremia), driving the Na:K ratio down. In our analysis of 5,383 single-agent canine reports, hyperkalaemia was reported in 761 cases (14.1%) and a low Na:K ratio in 335 cases (6.2%).

Is there a generic Vetoryl, and why does trilostane cost so much?

There is currently no FDA-approved generic trilostane (ANADA) in the United States. Dechra Veterinary Products holds NADA 141-291 for Vetoryl, making it a brand-only medication. Compounded alternatives made from bulk chemical powder are strongly discouraged by veterinary endocrinologists due to documented potency inconsistencies that increase the risk of under-treatment or fatal Addisonian crises.

How often does my dog need ACTH-stimulation testing while on trilostane?

Standard clinical protocol requires an ACTH-stimulation test and serum electrolyte panel at 10–14 days, 30 days, and 90 days after initiating therapy or changing the dose. Once stable, testing is repeated every 3 to 6 months indefinitely. The test must be started 4 to 6 hours after the morning Vetoryl capsule given with a meal.

Sources

• FDA Center for Veterinary Medicine (CVM): Animal Drugs @ FDA — Vetoryl (trilostane) NADA 141-291 Approval Information
• U.S. Federal Register: New Animal Drugs; Trilostane (NADA 141-291 Approval Notice, Doc. E9-10927)
• openFDA API: Animal and Veterinary Drug Adverse Event Reporting Database
• National Institutes of Health (DailyMed): VETORYL Capsules (trilostane) Prescribing Information & Client Information Sheet
• Dechra Veterinary Products: Vetoryl Capsules (trilostane) Important Safety Information & Technical Brochure
• Journal of Veterinary Internal Medicine (PMC5855282): Update on the use of trilostane in dogs: efficacy, safety, and monitoring protocols
• Veterinary Clinics of North America: Small Animal Practice (PMC6055912): Management of hypoadrenocorticism (Addison's disease) in dogs